tbuckley/cabot-search huggingface dataset:
Abstract 3071: Reversible Transmural Electrical Dyssynchrony in Pacing-Induced Congestive Heart Failure
Authors: Nilesh Mathuria, Jianwen Wang, April L Gilbert, Daryl G Schulz, Mihir Naware, Jeff Siou, Dorin Panescu, Keith A Youker, Hue-Teh Shih, Sherif F Nagueh, Dirar S Khoury
Journal: Circulation (2007)

Introduction: Inter and Intra-ventricular dyssynchrony can develop during congestive heart failure (CHF). We investigated transmural electrical conduction properties within the LV wall during CHF and subsequent recovery. Methods: Biventricular pacemakers were implanted in 8 normal mongrel dogs (mean weight: 38 kg), and continuous RV pacing (230 –250 bpm) was initiated to induce CHF. Echocardiography, catheterization, and LV myocardial biopsy were performed biweekly while pacing was temporarily stopped. At each catheterization, an intracardiac electrode-catheter was placed at the LV endocardium against the pacemaker coronary sinus lead tip located at the LV epicardium. Intrinsic transmural electrical conduction delay was measured by recording endocardial electrograms via the electrode-catheter and epicardial electrograms via the pacemaker coronary sinus lead, both in posterolateral LV. The conduction delay was also assessed during LV pacing via the endocardial catheter and measuring the time to the coronary sinus lead tip. Pacing was stopped in 4 dogs with CHF to allow for recovery of function. All times were corrected for heart rate. Results: All dogs developed CHF within 2– 4 wks of pacing from baseline (EF: 27±8 vs. 49±4%; LVEDP: 20±9 vs. 6±3 mmHg; QRS: 98±8 vs. 70±14 msec with no LBBB). There was no change in LV wall thickness during CHF compared to baseline (0.9 cm), while LV myocyte size increased (21.7±6.6 vs. 16.2±1.5 μm). Transmural endocardial-to-epicardial intrinsic electrical conduction time lengthened during CHF compared to baseline (35±13 vs. 10±5msec, P&lt;0.001). In dogs recovering from CHF 2– 4 wks after cessation of pacing, intrinsic transmural endocardial-to-epicardial conduction time shortened compared to CHF (10±9 vs. 39±1ms, n=4), which was consistent with LV endocardial pacing (recovery: 47.5±6 ms; CHF: 70.7±9 ms, n=3). Conclusions: Electrical transmural dyssynchrony develops as a consequence of pacing-induced CHF, and is reversible upon recovery of cardiac function. These changes are not associated with LV wall thickness. This novel finding suggests another aspect of ventricular dyssynchrony that may not be reflected by routine noninvasive modalities and warrants further investigation.
<i>QuickStats:</i> Age-Adjusted Death Rates,* by State — United States,<sup /> 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

DC = District of Columbia.* Deaths per 100,000, age-adjusted to the 2000 U.S. standard population.† The U.S. rate was 731.9 deaths per 100,000 standard population in 2017.In 2017, the overall U.S. death rate was 731.9 per 100,000 standard population; rates varied by state.The five states with the highest age-adjusted death rates were West Virginia (957.1 deaths per 100,000 standard population), Mississippi (951.3),Kentucky (929.9),Alabama (917.7), and Oklahoma (902.4).The five states with the lowest death rates were Hawaii (584.9),California (618.7)
Two intraluminal duodenal diverticula treated with a “clip-assisted incision” technique
Authors: Yilong Feng, Liwen Guan, Liansong Ye, Bing Hu
Journal: Endoscopy (2021)

A 37-year-old woman presented to the emergency department with an 8-year history of recurrent melena. Laboratory tests showed a hemoglobin of 76 g/L. Esophagogastroduodenoscopy showed a huge mass in the descending duodenum; however, within a few seconds, the mass collapsed. After a careful inspection of the duodenum, two closely located intraluminal diverticula were identified ([Fig. 1]). The previously noticed mass had been formed by eversion of the wall of one diverticulum. The true lumen was hidden within the septum between the two diverticula. A barium examination and computed tomography scan confirmed the diagnosis ([Fig. 2] and [Fig. 3]).
Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma—Is It Based on Evidence or Clinical Wisdom?
Authors: Lorenzo Gervaso, Florian Lordick, Nicola Fazio
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Correction to: PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling
Authors: Bing Yao, Tao Gui, Xiangwei Zeng, Yexuan Deng, Zhi Wang, Ying Wang, Dongjun Yang, Qixiang Li, Peipei Xu, Ruifeng Hu, Xinyu Li, Bing Chen, Jin Wang, Ke Zen, Haitao Li, Melissa J. Davis, Marco J. Herold, Hua-Feng Pan, Zhi-Wei Jiang, David C. S. Huang, Ming Liu, Junyi Ju, Quan Zhao
Journal: Genome Medicine (2021)
796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
Authors: V. Makker, M.H. Taylor, C. Aghajanian, A.L. Cohn, M.S. Brose, C. DiSimone, A. Cao, L. Suttner, A. Loboda, R. Cristescu, P. Jelinic, A. Snyder, M. Nebozhyn, J. Lunceford, R. Orlowski, L. Dutta, J. Matsui, C. Dutcus, Y. Minoshima, M. Messing
Journal: Annals of Oncology (2021)
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
Authors: Ghayas C. Issa, Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning, Nicholas J. Short, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood Cancer Journal (2021)

Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 without significant impact on prognosis, except for patients with ≥2 mutations with lower overall survival (OS). KMT2Ar AML had worse outcomes compared with diploid AML when newly diagnosed and at relapse, especially following second salvage (median OS of 2.4 vs 4.8 months, P < 0.0001). Therapy-related KMT2Ar AML (t-AML) had worse outcomes compared with de novo KMT2Ar AML (median OS of 0.7 years vs 1.4 years, P < 0.0001). Allogeneic hematopoietic stem cell transplant (allo-HSCT) in first remission was associated with improved OS (5-year, 52 vs 14% for no allo-HSCT, P < 0.0001). In a multivariate analysis, translocation subtypes causing KMT2Ar did not predict survival, unlike age and allo-HSCT. In conclusion, KMT2Ar was associated with adverse outcomes regardless of translocation subtype. Therefore, AML risk stratification guidelines should include all KMT2Ar as adverse.
Our Limited Knowledge of Youth Suicide Risk and Firearm Access
Authors: Eric W. Fleegler
Journal: JAMA Network Open (2021)

Talia L. Spark, PhD, MS; Erin Wright-Kelly, DrPH, MA; Ming Ma, MD, MPH; Katherine A. James, PhD, MS, MSPH; Colleen E. Reid, PhD, MPH; Ashley Brooks-Russell, PhD, MPH
Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles
Authors: Dhanu Gupta, Oscar P. B. Wiklander, André Görgens, Mariana Conceição, Giulia Corso, Xiuming Liang, Yiqi Seow, Sriram Balusu, Ulrika Feldin, Beklem Bostancioglu, Rim Jawad, Doste R. Mamand, Yi Xin Fiona Lee, Justin Hean, Imre Mäger, Thomas C. Roberts, Manuela Gustafsson, Dara K. Mohammad, Helena Sork, Alexandra Backlund, Per Lundin, Antonin de Fougerolles, C. I. Edvard Smith, Matthew J. A. Wood, Roosmarijn E. Vandenbroucke, Joel Z. Nordin, Samir El-Andaloussi
Journal: Nature Biomedical Engineering (2021)
628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Authors: M.K. Hardwick, E. Esplin, B. Mazzerelli, D. Morris, S. Heron, J. Veys, A. Engelman, P. Dato, R. Bevan-Thomas, D. Wise, R. Cornell, A. Berger, S. Nielsen, K. Hatchell, R. Nussbaum, M. Gazi, C.M. Pieczonka, L. Belkoff, D.J. Cahn, N.D. Shore
Journal: Annals of Oncology (2021)
Research Needs for Inpatient Management of Severe Alcohol Withdrawal Syndrome: An Official American Thoracic Society Research Statement
Authors: Tessa L. Steel, Majid Afshar, Scott Edwards, Sarah E. Jolley, Christine Timko, Brendan J. Clark, Ivor S. Douglas, Amy L. Dzierba, Hayley B. Gershengorn, Nicholas W. Gilpin, Dwayne W. Godwin, Catherine L. Hough, José R. Maldonado, Anuj B. Mehta, Lewis S. Nelson, Mayur B. Patel, Darius A. Rastegar, Joanna L. Stollings, Boris Tabakoff, Judith A. Tate, Adrian Wong, Ellen L. Burnham
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Background: Severe alcohol withdrawal syndrome (SAWS) is highly morbid, costly, and common among hospitalized patients, yet minimal evidence exists to guide inpatient management. Research needs in this field are broad, spanning the translational science spectrum. Goals: This research statement aims to describe what is known about SAWS, identify knowledge gaps, and offer recommendations for research in each domain of the Institute of Medicine T0-T4 continuum to advance the care of hospitalized patients who experience SAWS. Methods: Clinicians and researchers with unique and complementary expertise in basic, clinical, and implementation research related to unhealthy alcohol consumption and alcohol withdrawal were invited to participate in a workshop at the American Thoracic Society 2019 International Conference. The committee was subdivided into four groups on the basis of interest and expertise: T0-T1 (basic science research with translation to humans), T2 (research translating to patients), T3 (research translating to clinical practice), and T4 (research translating to communities). A medical librarian conducted a pragmatic literature search to facilitate this work, and committee members reviewed and supplemented the resulting evidence, identifying key knowledge gaps. Results: The committee identified several investigative opportunities to advance the care of patients with SAWS in each domain of the translational science spectrum. Major themes included 1) the need to investigate non-γ-aminobutyric acid pathways for alcohol withdrawal syndrome treatment; 2) harnessing retrospective and electronic health record data to identify risk factors and create objective severity scoring systems, particularly for acutely ill patients with SAWS; 3) the need for more robust comparative-effectiveness data to identify optimal SAWS treatment strategies; and 4) recommendations to accelerate implementation of effective treatments into practice. Conclusions: The dearth of evidence supporting management decisions for hospitalized patients with SAWS, many of whom require critical care, represents both a call to action and an opportunity for the American Thoracic Society and larger scientific communities to improve care for a vulnerable patient population. This report highlights basic, clinical, and implementation research that diverse experts agree will have the greatest impact on improving care for hospitalized patients with SAWS.
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention
Authors: Alexander E. Sullivan, Michael G. Nanna, Tracy Y. Wang, Deepak L. Bhatt, Dominick J. Angiolillo, Roxana Mehran, Subhash Banerjee, Sarah Cantrell, W. Schuyler Jones, Jennifer A. Rymer, Jeffrey B. Washam, Sunil V. Rao, E. Magnus Ohman
Journal: Journal of the American College of Cardiology (2021)
593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Authors: C.S. Higano, S. Dizdarevic, S. Sundar, N. Agarwal, M. Essler, D. Song, S. George, N.D. Shore, M. Kurtinecz, F. Verholen, P. Sandström, O. Sartor, D.J. George
Journal: Annals of Oncology (2021)
A prospective evaluation of AI-augmented epidemiology to forecast COVID-19 in the USA and Japan
Authors: Sercan Ö. Arık, Joel Shor, Rajarishi Sinha, Jinsung Yoon, Joseph R. Ledsam, Long T. Le, Michael W. Dusenberry, Nathanael C. Yoder, Kris Popendorf, Arkady Epshteyn, Johan Euphrosine, Elli Kanal, Isaac Jones, Chun-Liang Li, Beth Luan, Joe Mckenna, Vikas Menon, Shashank Singh, Mimi Sun, Ashwin Sura Ravi, Leyou Zhang, Dario Sava, Kane Cunningham, Hiroki Kayama, Thomas Tsai, Daisuke Yoneoka, Shuhei Nomura, Hiroaki Miyata, Tomas Pfister
Journal: npj Digital Medicine (2021)

Abstract The COVID-19 pandemic has highlighted the global need for reliable models of disease spread. We propose an AI-augmented forecast modeling framework that provides daily predictions of the expected number of confirmed COVID-19 deaths, cases, and hospitalizations during the following 4 weeks. We present an international, prospective evaluation of our models’ performance across all states and counties in the USA and prefectures in Japan. Nationally, incident mean absolute percentage error (MAPE) for predicting COVID-19 associated deaths during prospective deployment remained consistently &lt;8% (US) and &lt;29% (Japan), while cumulative MAPE remained &lt;2% (US) and &lt;10% (Japan). We show that our models perform well even during periods of considerable change in population behavior, and are robust to demographic differences across different geographic locations. We further demonstrate that our framework provides meaningful explanatory insights with the models accurately adapting to local and national policy interventions. Our framework enables counterfactual simulations, which indicate continuing Non-Pharmaceutical Interventions alongside vaccinations is essential for faster recovery from the pandemic, delaying the application of interventions has a detrimental effect, and allow exploration of the consequences of different vaccination strategies. The COVID-19 pandemic remains a global emergency. In the face of substantial challenges ahead, the approach presented here has the potential to inform critical decisions.
452P Predicting response to bevacizumab in colorectal cancer by integrating radiomics to clinical and genomic features
Authors: G. Milanese, M. Maddalo, L. Leo, M. Lecchini, L. Bottarelli, L. Gnetti, N. Campanini, G. Pedrazzi, C. Azzoni, C. Bozzetti, A. Zavani, P. Caruana, E.M. Silini, N. Sverzellati, F. Negri
Journal: Annals of Oncology (2021)
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity
Authors: Rita E Chen, Brittany K Smith, John M Errico, David N Gordon, Emma S Winkler, Laura A VanBlargan, Chandni Desai, Scott A Handley, Kimberly A Dowd, Emerito Amaro-Carambot, M Jane Cardosa, Carlos A Sariol, Esper G Kallas, Rafick-Pierre Sékaly, Nikos Vasilakis, Daved H Fremont, Stephen S Whitehead, Theodore C Pierson, Michael S Diamond
Journal: Cell Host & Microbe (2021)
1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
Authors: S. Cedres, J.D. Assaf, P. Iranzo Gomez, A. Callejo Perez, N. Pardo Aranda, A. Navarro, A. Martinez-Marti, D.H. Marmolejo Castaneda, M.A. Rezqallah Aron, A. Pedrola, J. Gonzalo, J. Frigola, C. Carbonell, R. Amat, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2021)
1121P Prognostic value of soluble transforming growth factor-β and soluble programmed death-ligand 1 in patients with non-functioning neuroendocrine tumors or pheochromocytomas/paragangliomas
Authors: J.S. Yoon, J-H. Bang, A-R. Nam, H-R. Seo, J-M. Kim, K-S. Oh, T-Y. Kim, D-Y. Oh
Journal: Annals of Oncology (2021)
LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Authors: C.U. Blank, I.L.M. Reijers, J.M. Versluis, A.M. Menzies, P. Dimitriadis, M.W. Wouters, R.P.M. Saw, W.M.C. Klop, T.E. Pennington, L.J.W. Bosch, S. Cornelissen, L.G. Grijpink-Ongering, M.J.C. Gregorio, M. Lopez-Yurda, R.V. Rawson, A.J. Spillane, B.A. van de Wiel, R.A. Scolyer, A.C.J. van Akkooi, G.V. Long
Journal: Annals of Oncology (2021)
P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
Authors: M. Fedyanin, F. Moiseenko, M. Lyadova, E. Vorobeva, O. Gladkov, V. Petkau, A. Fateeva, E. Kuzmina, O. Novikova, V. Chubenko, N. Abduloeva, A. Kudryavtsev, E. Ignatova, R. Shakirov, O. Pardabekova, L. Kindyalova, S. Pelikh, S. Tjulandin, A. Tryakin
Journal: Annals of Oncology (2021)
Parallel subgenome structure and divergent expression evolution of allo-tetraploid common carp and goldfish
Authors: Jiong-Tang Li, Qi Wang, Mei-Di Huang Yang, Qing-Song Li, Ming-Shu Cui, Zai-Jie Dong, Hong-Wei Wang, Ju-Hua Yu, Yu-Jie Zhao, Chen-Ru Yang, Ya-Xin Wang, Xiao-Qing Sun, Yan Zhang, Ran Zhao, Zhi-Ying Jia, Xi-Yin Wang
Journal: Nature Genetics (2021)

How two subgenomes in allo-tetraploids adapt to coexistence and coordinate through structure and expression evolution requires extensive studies. In the present study, we report an improved genome assembly of allo-tetraploid common carp, an updated genome annotation of allo-tetraploid goldfish and the chromosome-scale assemblies of a progenitor-like diploid Puntius tetrazona and an outgroup diploid Paracanthobrama guichenoti. Parallel subgenome structure evolution in the allo-tetraploids was featured with equivalent chromosome components, higher protein identities, similar transposon divergence and contents, homoeologous exchanges, better synteny level, strong sequence compensation and symmetric purifying selection. Furthermore, we observed subgenome expression divergence processes in the allo-tetraploids, including inter-/intrasubgenome trans-splicing events, expression dominance, decreased expression levels, dosage compensation, stronger expression correlation, dynamic functionalization and balancing of differential expression. The potential disorders introduced by different progenitors in the allo-tetraploids were hypothesized to be alleviated by increasing structural homogeneity and performing versatile expression processes. Resequencing three common carp strains revealed two major ecotypes and uncovered candidate genes relevant to growth and survival rate.
1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
Authors: M. Wislez, J. Mazieres, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M-A. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, V. Westeel, M. Antoine, D. Damotte
Journal: Annals of Oncology (2021)
419P XELOX/XELIRI alternative regimen as first-line treatment of metastatic colorectal cancer (CCRCTO-2: TROT): A phase II study
Authors: Y. Han, R. Zhang, Y. Liu, P. Han, H. Yuan, X. Wei, H. Chen, L. Bai, Y. Zhang, J. Zhu
Journal: Annals of Oncology (2021)
47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
Authors: M. Droz Dit Busset, W.L. Shaib, K. Mody, N. Personeni, N. Damjanov, W.P. Harris, F. Bergamo, G. Brandi, G. Masi, T.R. Halfdanarson, V. Tam, L.W. Goff, J. Knox, A. Hollebecque, T. Macarulla Mercade, F. Cantero, M. Saulay, S. Braun, M. Javle, M. Borad
Journal: Annals of Oncology (2021)
COVID-19 Pandemic and Exercise (COPE) trial: a multigroup pragmatic randomised controlled trial examining effects of app-based at-home exercise programs on depressive symptoms
Authors: Eli Puterman, Benjamin Hives, Nicole Mazara, Nikol Grishin, Joshua Webster, Stacey Hutton, Michael Stephen Koehle, Yan Liu, Mark R Beauchamp
Journal: British Journal of Sports Medicine (2021)

The number of adults across the globe with significant depressive symptoms has grown substantially during the COVID-19 pandemic. The extant literature supports exercise as a potent behaviour that can significantly reduce depressive symptoms in clinical and non-clinical populations.Using a suite of mobile applications, at-home exercise, including high intensity interval training (HIIT) and/or yoga, was completed to reduce depressive symptoms in the general population in the early months of the pandemic.A 6-week, parallel, multiarm, pragmatic randomised controlled trial was completed with four groups: (1) HIIT, (2) Yoga, (3) HIIT+yoga, and (4) waitlist control (WLC). Low active, English-speaking, non-retired Canadians aged 18-64 years were included. Depressive symptoms were measured at baseline and weekly following randomisation.A total of 334 participants were randomised to one of four groups. No differences in depressive symptoms were evident at baseline. The results of latent growth modelling showed significant treatment effects in depressive symptoms for each active group compared with the WLC, with small effect sizes (ESs) in the community-based sample of participants. Treatment groups were not significantly different from each other. Effect sizes were very large (eg, week 6 ES range=-2.34 to -2.52) when restricting the analysis only to participants with high depressive symptoms at baseline.At-home exercise is a potent behaviour to improve mental health in adults during the pandemic, especially in those with increased levels of depressive symptoms. Promotion of at-home exercise may be a global public health target with important personal, social and economic implications as the world emerges scathed by the pandemic.NCT04400279.